INN name:
|
Erdafitinib
|
|||||||||||||||
Lab codes:
|
JNJ-42756493
|
|||||||||||||||
Chemical name:
|
N1-(3,5-dimethoxyphenyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]-N2-(propan-2-yl)ethane-1,2-diamine
|
|||||||||||||||
Molecular formula:
|
C25H30N6O2
|
|||||||||||||||
Chemical Structure:
|
 |
|||||||||||||||
CAS Registry Number:
|
1346242-81-6
|
|||||||||||||||
Originator:
|
Astex
Therapeutics
|
|||||||||||||||
Developer:
|
Janssen
Research & Development
|
|||||||||||||||
Class:
|
Antineoplastics
|
|||||||||||||||
Mechanism of Action:
|
Fibroblast
growth factor receptor antagonists
|
|||||||||||||||
WHO ATC code:
|
L01
(Antineoplastic Agents)
|
|||||||||||||||
EPhMRA code:
|
L1
(Antineoplastics)
|
|||||||||||||||
Clinical Trials:
|
||||||||||||||||
Recent activities on the
drug:
|
||||||||||||||||
Friday, 18 September 2015
Erdafitinib
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment